Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) Stock Competitors & Peer Comparison

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, VRTX has a market cap of 129.6B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while VRTX trades at $520.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas VRTX's P/E ratio is 26.83. In terms of profitability, PHAT's ROE is +0.26%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, PHAT is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check VRTX's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, REGN has a market cap of 82.2B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while REGN trades at $810.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas REGN's P/E ratio is 17.49. In terms of profitability, PHAT's ROE is +0.26%, compared to REGN's ROE of +0.14%. Regarding short-term risk, PHAT is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check REGN's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while VRNA trades at $106.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas VRNA's P/E ratio is -102.80. In terms of profitability, PHAT's ROE is +0.26%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, PHAT is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check VRNA's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, MRNA has a market cap of 68.6B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while MRNA trades at $183.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas MRNA's P/E ratio is -21.22. In terms of profitability, PHAT's ROE is +0.26%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, PHAT is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for PHAT.Check MRNA's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, ARGX has a market cap of 61.5B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while ARGX trades at $973.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas ARGX's P/E ratio is 35.63. In terms of profitability, PHAT's ROE is +0.26%, compared to ARGX's ROE of +0.24%. Regarding short-term risk, PHAT is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check ARGX's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while SGEN trades at $228.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas SGEN's P/E ratio is -57.19. In terms of profitability, PHAT's ROE is +0.26%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, PHAT is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check SGEN's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, RVMD has a market cap of 41B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while RVMD trades at $192.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas RVMD's P/E ratio is -21.85. In terms of profitability, PHAT's ROE is +0.26%, compared to RVMD's ROE of -0.96%. Regarding short-term risk, PHAT is more volatile compared to RVMD. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check RVMD's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, RVMDW has a market cap of 39.3B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while RVMDW trades at $9.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas RVMDW's P/E ratio is -1.13. In terms of profitability, PHAT's ROE is +0.26%, compared to RVMDW's ROE of -0.96%. Regarding short-term risk, PHAT is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for PHAT.Check RVMDW's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, ONC has a market cap of 39.1B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while ONC trades at $367.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas ONC's P/E ratio is 64.38. In terms of profitability, PHAT's ROE is +0.26%, compared to ONC's ROE of +0.14%. Regarding short-term risk, PHAT is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check ONC's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, ALNY has a market cap of 32.7B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while ALNY trades at $254.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas ALNY's P/E ratio is 44.02. In terms of profitability, PHAT's ROE is +0.26%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, PHAT is more volatile compared to ALNY. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check ALNY's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, ROIV has a market cap of 28.2B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while ROIV trades at $38.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas ROIV's P/E ratio is -37.09. In terms of profitability, PHAT's ROE is +0.26%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, PHAT is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check ROIV's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, INSM has a market cap of 26.2B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while INSM trades at $121.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas INSM's P/E ratio is -29.44. In terms of profitability, PHAT's ROE is +0.26%, compared to INSM's ROE of -1.11%. Regarding short-term risk, PHAT is more volatile compared to INSM. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check INSM's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, INCY has a market cap of 25.3B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while INCY trades at $127.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas INCY's P/E ratio is 16.75. In terms of profitability, PHAT's ROE is +0.26%, compared to INCY's ROE of +0.30%. Regarding short-term risk, PHAT is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check INCY's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, BNTX has a market cap of 24.6B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while BNTX trades at $101.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas BNTX's P/E ratio is -12.71. In terms of profitability, PHAT's ROE is +0.26%, compared to BNTX's ROE of -0.09%. Regarding short-term risk, PHAT is more volatile compared to BNTX. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check BNTX's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, GMAB has a market cap of 21.3B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while GMAB trades at $35.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas GMAB's P/E ratio is 26.14. In terms of profitability, PHAT's ROE is +0.26%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, PHAT is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check GMAB's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, UTHR has a market cap of 20.9B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while UTHR trades at $498.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas UTHR's P/E ratio is 17.64. In terms of profitability, PHAT's ROE is +0.26%, compared to UTHR's ROE of +0.20%. Regarding short-term risk, PHAT is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check UTHR's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while BGNE trades at $184.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas BGNE's P/E ratio is -22.55. In terms of profitability, PHAT's ROE is +0.26%, compared to BGNE's ROE of +0.14%. Regarding short-term risk, PHAT is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check BGNE's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while DNA-WT trades at $0.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, PHAT's ROE is +0.26%, compared to DNA-WT's ROE of -0.60%. Regarding short-term risk, PHAT is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for PHAT.Check DNA-WT's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, JAZZ has a market cap of 15.2B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while JAZZ trades at $240.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas JAZZ's P/E ratio is 9.00. In terms of profitability, PHAT's ROE is +0.26%, compared to JAZZ's ROE of +0.21%. Regarding short-term risk, PHAT is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check JAZZ's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, ASND has a market cap of 14.8B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while ASND trades at $236.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas ASND's P/E ratio is -98.18. In terms of profitability, PHAT's ROE is +0.26%, compared to ASND's ROE of +1.90%. Regarding short-term risk, PHAT is more volatile compared to ASND. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check ASND's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, NBIX has a market cap of 14.5B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while NBIX trades at $142.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas NBIX's P/E ratio is 20.80. In terms of profitability, PHAT's ROE is +0.26%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, PHAT is more volatile compared to NBIX. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check NBIX's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, EXEL has a market cap of 14.4B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while EXEL trades at $58.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas EXEL's P/E ratio is 16.35. In terms of profitability, PHAT's ROE is +0.26%, compared to EXEL's ROE of +0.42%. Regarding short-term risk, PHAT is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check EXEL's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, SMMT has a market cap of 13.5B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while SMMT trades at $17.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas SMMT's P/E ratio is -15.09. In terms of profitability, PHAT's ROE is +0.26%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, PHAT is more volatile compared to SMMT. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check SMMT's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, HALO has a market cap of 13.2B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while HALO trades at $114.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas HALO's P/E ratio is 20.79. In terms of profitability, PHAT's ROE is +0.26%, compared to HALO's ROE of +1.81%. Regarding short-term risk, PHAT is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check HALO's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, BBIO has a market cap of 13B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while BBIO trades at $69.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas BBIO's P/E ratio is -17.80. In terms of profitability, PHAT's ROE is +0.26%, compared to BBIO's ROE of +0.32%. Regarding short-term risk, PHAT is more volatile compared to BBIO. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check BBIO's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while KRTX trades at $329.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas KRTX's P/E ratio is -28.09. In terms of profitability, PHAT's ROE is +0.26%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, PHAT is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check KRTX's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, BMRN has a market cap of 12.4B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while BMRN trades at $63.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas BMRN's P/E ratio is 30.80. In terms of profitability, PHAT's ROE is +0.26%, compared to BMRN's ROE of +0.01%. Regarding short-term risk, PHAT is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check BMRN's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, MDGL has a market cap of 12.1B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while MDGL trades at $523.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas MDGL's P/E ratio is -40.78. In terms of profitability, PHAT's ROE is +0.26%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, PHAT is more volatile compared to MDGL. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check MDGL's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while TECH trades at $72.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas TECH's P/E ratio is 37.36. In terms of profitability, PHAT's ROE is +0.26%, compared to TECH's ROE of +0.09%. Regarding short-term risk, PHAT is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check TECH's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while RNAM trades at $72.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas RNAM's P/E ratio is -17.39. In terms of profitability, PHAT's ROE is +0.26%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, PHAT is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check RNAM's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, AXSM has a market cap of 10.6B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while AXSM trades at $204.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas AXSM's P/E ratio is -53.65. In terms of profitability, PHAT's ROE is +0.26%, compared to AXSM's ROE of -2.56%. Regarding short-term risk, PHAT is more volatile compared to AXSM. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check AXSM's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, TWST has a market cap of 10.3B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while TWST trades at $167.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas TWST's P/E ratio is -74.69. In terms of profitability, PHAT's ROE is +0.26%, compared to TWST's ROE of -0.30%. Regarding short-term risk, PHAT is more volatile compared to TWST. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check TWST's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, TXG has a market cap of 10B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while TXG trades at $80.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas TXG's P/E ratio is -134.07. In terms of profitability, PHAT's ROE is +0.26%, compared to TXG's ROE of -0.09%. Regarding short-term risk, PHAT is less volatile compared to TXG. This indicates lower risk in terms of short-term price fluctuations for PHAT.Check TXG's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, KRYS has a market cap of 9.8B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while KRYS trades at $350.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas KRYS's P/E ratio is 41.84. In terms of profitability, PHAT's ROE is +0.26%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, PHAT is less volatile compared to KRYS. This indicates lower risk in terms of short-term price fluctuations for PHAT.Check KRYS's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, ARWR has a market cap of 9.7B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while ARWR trades at $71.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas ARWR's P/E ratio is -30.57. In terms of profitability, PHAT's ROE is +0.26%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, PHAT is less volatile compared to ARWR. This indicates lower risk in terms of short-term price fluctuations for PHAT.Check ARWR's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, KYMR has a market cap of 9.7B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while KYMR trades at $121.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas KYMR's P/E ratio is -36.77. In terms of profitability, PHAT's ROE is +0.26%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, PHAT is more volatile compared to KYMR. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check KYMR's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while RXDX trades at $199.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas RXDX's P/E ratio is -56.47. In terms of profitability, PHAT's ROE is +0.26%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, PHAT is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check RXDX's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, PTGX has a market cap of 9.3B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while PTGX trades at $145.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas PTGX's P/E ratio is 140.76. In terms of profitability, PHAT's ROE is +0.26%, compared to PTGX's ROE of +0.12%. Regarding short-term risk, PHAT is more volatile compared to PTGX. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check PTGX's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while NUVL trades at $123.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas NUVL's P/E ratio is -21.79. In terms of profitability, PHAT's ROE is +0.26%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, PHAT is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check NUVL's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while CRNX trades at $84.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas CRNX's P/E ratio is -16.86. In terms of profitability, PHAT's ROE is +0.26%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, PHAT is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check CRNX's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, IBRX has a market cap of 8.9B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while IBRX trades at $9.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas IBRX's P/E ratio is -8.71. In terms of profitability, PHAT's ROE is +0.26%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, PHAT is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for PHAT.Check IBRX's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, TGTX has a market cap of 8.8B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while TGTX trades at $58.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas TGTX's P/E ratio is 20.71. In terms of profitability, PHAT's ROE is +0.26%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, PHAT is more volatile compared to TGTX. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check TGTX's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while IMGN trades at $31.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas IMGN's P/E ratio is -111.55. In terms of profitability, PHAT's ROE is +0.26%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, PHAT is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check IMGN's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, CAI has a market cap of 8.7B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while CAI trades at $31.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas CAI's P/E ratio is 86.12. In terms of profitability, PHAT's ROE is +0.26%, compared to CAI's ROE of +0.19%. Regarding short-term risk, PHAT is more volatile compared to CAI. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check CAI's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, PCVX has a market cap of 8.5B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while PCVX trades at $59.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas PCVX's P/E ratio is -7.72. In terms of profitability, PHAT's ROE is +0.26%, compared to PCVX's ROE of -0.38%. Regarding short-term risk, PHAT is more volatile compared to PCVX. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check PCVX's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, CYTK has a market cap of 8.4B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while CYTK trades at $67.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas CYTK's P/E ratio is -9.36. In terms of profitability, PHAT's ROE is +0.26%, compared to CYTK's ROE of +1.64%. Regarding short-term risk, PHAT is more volatile compared to CYTK. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check CYTK's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while BPMC trades at $129.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas BPMC's P/E ratio is -51.58. In terms of profitability, PHAT's ROE is +0.26%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, PHAT is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check BPMC's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, APGE has a market cap of 8.4B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while APGE trades at $135.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas APGE's P/E ratio is -31.19. In terms of profitability, PHAT's ROE is +0.26%, compared to APGE's ROE of -0.30%. Regarding short-term risk, PHAT is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check APGE's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, PRAX has a market cap of 8.3B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while PRAX trades at $299.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas PRAX's P/E ratio is -23.11. In terms of profitability, PHAT's ROE is +0.26%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, PHAT is more volatile compared to PRAX. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check PRAX's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while CERE trades at $44.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas CERE's P/E ratio is -16.47. In terms of profitability, PHAT's ROE is +0.26%, compared to CERE's ROE of -0.72%. Regarding short-term risk, PHAT is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check CERE's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, SYRE has a market cap of 8B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while SYRE trades at $91.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas SYRE's P/E ratio is -47.19. In terms of profitability, PHAT's ROE is +0.26%, compared to SYRE's ROE of -0.24%. Regarding short-term risk, PHAT is more volatile compared to SYRE. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check SYRE's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, IMVT has a market cap of 7.7B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while IMVT trades at $37.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas IMVT's P/E ratio is -13.18. In terms of profitability, PHAT's ROE is +0.26%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, PHAT is more volatile compared to IMVT. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check IMVT's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, ABVX has a market cap of 7.6B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while ABVX trades at $98.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas ABVX's P/E ratio is -19.69. In terms of profitability, PHAT's ROE is +0.26%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, PHAT is less volatile compared to ABVX. This indicates lower risk in terms of short-term price fluctuations for PHAT.Check ABVX's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, IONS has a market cap of 7.5B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while IONS trades at $46.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas IONS's P/E ratio is -13.73. In terms of profitability, PHAT's ROE is +0.26%, compared to IONS's ROE of -1.11%. Regarding short-term risk, PHAT is more volatile compared to IONS. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check IONS's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while MTSR trades at $70.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas MTSR's P/E ratio is -23.58. In terms of profitability, PHAT's ROE is +0.26%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, PHAT is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check MTSR's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, BLTE has a market cap of 7B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while BLTE trades at $175.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas BLTE's P/E ratio is -92.73. In terms of profitability, PHAT's ROE is +0.26%, compared to BLTE's ROE of -0.16%. Regarding short-term risk, PHAT is more volatile compared to BLTE. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check BLTE's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, CGON has a market cap of 6.9B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while CGON trades at $78.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas CGON's P/E ratio is -29.09. In terms of profitability, PHAT's ROE is +0.26%, compared to CGON's ROE of -0.25%. Regarding short-term risk, PHAT is less volatile compared to CGON. This indicates lower risk in terms of short-term price fluctuations for PHAT.Check CGON's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while MRUS trades at $90.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas MRUS's P/E ratio is -17.05. In terms of profitability, PHAT's ROE is +0.26%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, PHAT is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check MRUS's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, RYTM has a market cap of 6.8B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while RYTM trades at $99.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas RYTM's P/E ratio is -31.78. In terms of profitability, PHAT's ROE is +0.26%, compared to RYTM's ROE of -0.80%. Regarding short-term risk, PHAT is more volatile compared to RYTM. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check RYTM's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while ACLX trades at $115.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas ACLX's P/E ratio is -28.27. In terms of profitability, PHAT's ROE is +0.26%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, PHAT is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check ACLX's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while RETA trades at $172.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas RETA's P/E ratio is -66.29. In terms of profitability, PHAT's ROE is +0.26%, compared to RETA's ROE of +0.47%. Regarding short-term risk, PHAT is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check RETA's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while CNTA trades at $40.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas CNTA's P/E ratio is -22.63. In terms of profitability, PHAT's ROE is +0.26%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, PHAT is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check CNTA's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, TVTX has a market cap of 5.8B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while TVTX trades at $60.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas TVTX's P/E ratio is -139.69. In terms of profitability, PHAT's ROE is +0.26%, compared to TVTX's ROE of -0.56%. Regarding short-term risk, PHAT is less volatile compared to TVTX. This indicates lower risk in terms of short-term price fluctuations for PHAT.Check TVTX's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, LGND has a market cap of 5.8B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while LGND trades at $297.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas LGND's P/E ratio is 31.84. In terms of profitability, PHAT's ROE is +0.26%, compared to LGND's ROE of +0.20%. Regarding short-term risk, PHAT is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check LGND's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, SRRK has a market cap of 5.8B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while SRRK trades at $51.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas SRRK's P/E ratio is -13.96. In terms of profitability, PHAT's ROE is +0.26%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, PHAT is less volatile compared to SRRK. This indicates lower risk in terms of short-term price fluctuations for PHAT.Check SRRK's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, ORKA has a market cap of 5.6B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while ORKA trades at $94.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas ORKA's P/E ratio is -48.13. In terms of profitability, PHAT's ROE is +0.26%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, PHAT is more volatile compared to ORKA. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check ORKA's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, CRSP has a market cap of 5.6B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while CRSP trades at $59.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas CRSP's P/E ratio is -12.25. In terms of profitability, PHAT's ROE is +0.26%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, PHAT is less volatile compared to CRSP. This indicates lower risk in terms of short-term price fluctuations for PHAT.Check CRSP's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while CDTX trades at $221.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas CDTX's P/E ratio is -19.77. In terms of profitability, PHAT's ROE is +0.26%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, PHAT is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check CDTX's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, MIRM has a market cap of 5.6B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while MIRM trades at $90.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas MIRM's P/E ratio is -6.32. In terms of profitability, PHAT's ROE is +0.26%, compared to MIRM's ROE of -4.10%. Regarding short-term risk, PHAT is more volatile compared to MIRM. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check MIRM's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while ABCM trades at $23.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, PHAT's ROE is +0.26%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, PHAT is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check ABCM's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while ISEE trades at $39.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas ISEE's P/E ratio is -22.44. In terms of profitability, PHAT's ROE is +0.26%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, PHAT is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check ISEE's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, COGT has a market cap of 5.5B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while COGT trades at $32.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas COGT's P/E ratio is -15.17. In terms of profitability, PHAT's ROE is +0.26%, compared to COGT's ROE of -0.73%. Regarding short-term risk, PHAT is more volatile compared to COGT. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check COGT's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, PTCT has a market cap of 5.4B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while PTCT trades at $66.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas PTCT's P/E ratio is -28.01. In terms of profitability, PHAT's ROE is +0.26%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, PHAT is more volatile compared to PTCT. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check PTCT's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, DNTH has a market cap of 5.4B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while DNTH trades at $97.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas DNTH's P/E ratio is -23.25. In terms of profitability, PHAT's ROE is +0.26%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, PHAT is more volatile compared to DNTH. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check DNTH's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while APLS trades at $41.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas APLS's P/E ratio is 38.35. In terms of profitability, PHAT's ROE is +0.26%, compared to APLS's ROE of +0.40%. Regarding short-term risk, PHAT is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check APLS's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, ERAS has a market cap of 5.2B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while ERAS trades at $15.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas ERAS's P/E ratio is -16.17. In terms of profitability, PHAT's ROE is +0.26%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, PHAT is more volatile compared to ERAS. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check ERAS's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, DFTX has a market cap of 5.2B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while DFTX trades at $39.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas DFTX's P/E ratio is N/A. In terms of profitability, PHAT's ROE is +0.26%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, PHAT is more volatile compared to DFTX. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check DFTX's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, EWTX has a market cap of 4.8B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while EWTX trades at $45.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas EWTX's P/E ratio is -24.13. In terms of profitability, PHAT's ROE is +0.26%, compared to EWTX's ROE of -0.39%. Regarding short-term risk, PHAT is more volatile compared to EWTX. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check EWTX's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while TERN trades at $52.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas TERN's P/E ratio is -51.41. In terms of profitability, PHAT's ROE is +0.26%, compared to TERN's ROE of -0.20%. Regarding short-term risk, PHAT is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check TERN's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, MANE has a market cap of 4.7B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while MANE trades at $117.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas MANE's P/E ratio is -35.94. In terms of profitability, PHAT's ROE is +0.26%, compared to MANE's ROE of -0.38%. Regarding short-term risk, PHAT is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for PHAT.Check MANE's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while FOLD trades at $14.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas FOLD's P/E ratio is -161.00. In terms of profitability, PHAT's ROE is +0.26%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, PHAT is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check FOLD's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, IOVA has a market cap of 4.5B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while IOVA trades at $10.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas IOVA's P/E ratio is -13.96. In terms of profitability, PHAT's ROE is +0.26%, compared to IOVA's ROE of -0.41%. Regarding short-term risk, PHAT is less volatile compared to IOVA. This indicates lower risk in terms of short-term price fluctuations for PHAT.Check IOVA's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, ACAD has a market cap of 4.5B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while ACAD trades at $26.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas ACAD's P/E ratio is 11.89. In terms of profitability, PHAT's ROE is +0.26%, compared to ACAD's ROE of +0.32%. Regarding short-term risk, PHAT is more volatile compared to ACAD. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check ACAD's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while AKRO trades at $54.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas AKRO's P/E ratio is -14.57. In terms of profitability, PHAT's ROE is +0.26%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, PHAT is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check AKRO's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, ADPT has a market cap of 4.5B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while ADPT trades at $28.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas ADPT's P/E ratio is -67.95. In terms of profitability, PHAT's ROE is +0.26%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, PHAT is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for PHAT.Check ADPT's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while ALPN trades at $64.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas ALPN's P/E ratio is -101.52. In terms of profitability, PHAT's ROE is +0.26%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, PHAT is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check ALPN's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, PBLS has a market cap of 4.3B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while PBLS trades at $38.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas PBLS's P/E ratio is -19.64. In terms of profitability, PHAT's ROE is +0.26%, compared to PBLS's ROE of -0.15%. Regarding short-term risk, PHAT is less volatile compared to PBLS. This indicates lower risk in terms of short-term price fluctuations for PHAT.Check PBLS's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while OPT trades at $3.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas OPT's P/E ratio is -1.52. In terms of profitability, PHAT's ROE is +0.26%, compared to OPT's ROE of +1.18%. Regarding short-term risk, PHAT is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check OPT's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while PRTC trades at $17.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas PRTC's P/E ratio is -3.78. In terms of profitability, PHAT's ROE is +0.26%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, PHAT is more volatile compared to PRTC. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check PRTC's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while MRTX trades at $58.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas MRTX's P/E ratio is -4.82. In terms of profitability, PHAT's ROE is +0.26%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, PHAT is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check MRTX's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, CELC has a market cap of 4.1B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while CELC trades at $84.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas CELC's P/E ratio is -19.53. In terms of profitability, PHAT's ROE is +0.26%, compared to CELC's ROE of -3.51%. Regarding short-term risk, PHAT is more volatile compared to CELC. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check CELC's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, RLAY has a market cap of 4B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while RLAY trades at $18.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas RLAY's P/E ratio is -11.59. In terms of profitability, PHAT's ROE is +0.26%, compared to RLAY's ROE of -0.42%. Regarding short-term risk, PHAT is more volatile compared to RLAY. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check RLAY's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, ABCL has a market cap of 3.9B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while ABCL trades at $12.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas ABCL's P/E ratio is -23.44. In terms of profitability, PHAT's ROE is +0.26%, compared to ABCL's ROE of -0.17%. Regarding short-term risk, PHAT is more volatile compared to ABCL. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check ABCL's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while CPRX trades at $31.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas CPRX's P/E ratio is 12.30. In terms of profitability, PHAT's ROE is +0.26%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, PHAT is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check CPRX's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, TLX has a market cap of 3.8B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while TLX trades at $11.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas TLX's P/E ratio is 118.06. In terms of profitability, PHAT's ROE is +0.26%, compared to TLX's ROE of +0.07%. Regarding short-term risk, PHAT is more volatile compared to TLX. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check TLX's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, XENE has a market cap of 3.8B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while XENE trades at $38.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas XENE's P/E ratio is -8.30. In terms of profitability, PHAT's ROE is +0.26%, compared to XENE's ROE of -0.44%. Regarding short-term risk, PHAT is more volatile compared to XENE. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check XENE's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while RYZB trades at $62.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas RYZB's P/E ratio is -57.86. In terms of profitability, PHAT's ROE is +0.26%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, PHAT is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check RYZB's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while CBAY trades at $32.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas CBAY's P/E ratio is -32.81. In terms of profitability, PHAT's ROE is +0.26%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, PHAT is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check CBAY's competition here

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHAT stands at 602.7M. In comparison, IDYA has a market cap of 3.7B. Regarding current trading prices, PHAT is priced at $7.75 on the NASDAQ, while IDYA trades at $39.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHAT currently has a P/E ratio of -5.82, whereas IDYA's P/E ratio is -20.03. In terms of profitability, PHAT's ROE is +0.26%, compared to IDYA's ROE of -0.16%. Regarding short-term risk, PHAT is more volatile compared to IDYA. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check IDYA's competition here